A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers : positive impacts of the Lu177- PSMA treatment in the advanced stage of prostate cancer

dc.contributor.affiliationUnitec Institute of Technologyen_NZ
dc.contributor.authorVyas, Madhusudan
dc.contributor.authorFagan, Jessica
dc.contributor.authorShaikh, Shamim
dc.date.accessioned2019-10-02T21:47:04Z
dc.date.available2019-10-02T21:47:04Z
dc.date.issued2019-08-31
dc.date.updated2019-09-23T20:40:42Z
dc.description.abstractObjective To evaluate the impact/effects of Lutetium-177-PSMA based treatment in improving the quality of life in patients with advanced stage of prostate cancer (mCRPC) Methodology Epidemiology (Global data) Epidemiology (NZ Data) Diagnosis and staging Treatment plan Metastatic disease(mCRPC) Metastatic disease(mCRPC) Metastatic disease(mCRPC) treatment algorithm Metastatic disease(mCRPC) treatment review of literature Prostate specific membrane antigen (PSMA) and mCRPC Various Prostate specific membrane antigen (PSMA) ligands and radionuclides suitable for labelling Lu-177 PSMA based Metastatic disease(mCRPC) treatment review of literature Lu-177-PSMA Treatment outcomes Lu-177 based therapeutic radiopharmaceuticals based treatment outcomes Physiological outcomes of the treatment, at our clinical site QoL, Pain and PSA levels; relative comparison PSA response and QoLoutcomes to Lu-177-PSMA, at our clinical site Third line treatment v/s Lu-177-PSMA Third line treatment v/s Lu-177-PSMA;Feedback from patients Conclusion Referenceen_NZ
dc.identifier.bibliographicCitationVyas, M., Fagan, J., & Shaikh, S. (2019, September). A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers: Positive impacts of the Lu177- PSMA Treatment in the advanced stage of Prostate cancer. Paper presented at the NZIMRT/ANZSNM-2019, Rotorua, New Zealand.en_NZ
dc.identifier.urihttps://hdl.handle.net/10652/4714
dc.language.isoenen_NZ
dc.rightsAll rights reserveden_NZ
dc.rights.holderAuthorsen_NZ
dc.subjectcancer patientsen_NZ
dc.subjectprostate canceren_NZ
dc.subjecttheranosticsen_NZ
dc.subjectradionuclide therapyen_NZ
dc.subjectLu-177en_NZ
dc.subjectLutetium-177en_NZ
dc.subjectneuroendocrine tumours (NETs)en_NZ
dc.subjectNew Zealanden_NZ
dc.subjectmetastatic castration-resistant prostate cancer (mCRPC)en_NZ
dc.subjectmCRPCen_NZ
dc.subject.marsden1112 Oncology and Carcinogenesisen_NZ
dc.subject.marsden110313 Nuclear Medicine
dc.titleA ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers : positive impacts of the Lu177- PSMA treatment in the advanced stage of prostate canceren_NZ
dc.typeConference Contribution - Oral Presentationen_NZ
unitec.author.disciplineMedical Imaging
unitec.author.firstnameMadhusudan
unitec.author.lastnameVyas
unitec.author.pathwayHealth Care
unitec.author.staffid1501697
unitec.conference.edate2019-09-01
unitec.conference.locationRotorua, New Zealanden_NZ
unitec.conference.orgNew Zealand Institute of Medical Radiation Technology (NZIMRT)en_NZ
unitec.conference.orgAustralian and New Zealand Society of Nuclear Medicine (ANZSNM)en_NZ
unitec.conference.sdate2019-08-30
unitec.conference.titleNZIMRT/ANZSNM-2019en_NZ
unitec.identifier.roms64435en_NZ
unitec.identifier.roms64452
unitec.institution.studyareaHealth Sciences
unitec.peerreviewedyesen_NZ
unitec.publication.titleNZIMRT/ANZSNM-2019en_NZ
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Vyas, M. (2019).pdf
Size:
1.56 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
501 B
Format:
Item-specific license agreed upon to submission
Description: